Asia-Pacific Dementia Treatment Market Analysis 2026

Asia-Pacific Dementia Treatment Market Analysis from 2022 to 2034 Containing Market Size, Share along with its CAGR, Forecast and Trends

Asia-Pacific Dementia Treatment Market Report Description

Read a Detailed Qualitative analysis of the above report by requesting the free sample pages from Request for your Free Sample PDF/Online Access.

Competitive Landscape: Dementia Treatment Market

To meet the increasing demands of consumers the industry players are now investing and giving more attention to their research and development of Dementia Treatment so that they sustain and survive in the competition. ensuring a competitive edge. Robust distribution networks and adherence to quality standards amplify market presence, fostering an environment where agility and innovation define industry leaders.
 

Top Companies Market Share in Asia-Pacific Dementia Treatment Industry: (In no particular order of Rank)

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive)

Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Asia-Pacific Dementia Treatment Market Segmentation Analysis from 2022 till 2034

The Alzheimer's dementia type segment accounts for the largest market share and is expected to rise over the period. According to the Alzheimer's Association 2021 report, the US Food and Drug Administration (FDA) has approved five medications for Alzheimer's treatment: rivastigmine, galantamine, donepezil, memantine, and memantine coupled with donepezil. The study also found that the vast majority of patients who develop Alzheimer's disease are 65 years or older. This is known as late-onset Alzheimer's. Furthermore, in the United States, Alzheimer's dementia affects about 5.3% of persons aged 65 to 74, 13.8% of those aged 75 to 84, and 34.6% of people aged 85 and up. In addition, an estimated 6.2 million Americans aged 65 and older will be living with Alzheimer's dementia in 2021, with a predicted increase to 13.5 million by 2050.
(Source-https://www.mayoclinic.org/diseases-conditions/alzheimers-disease/in-depth/alzheimers/art-20048103)

Vascular dementia is the market's fastest-growing sector, defined as cognitive impairment caused by impaired blood flow to the brain. This type of dementia is commonly caused by a stroke or other vascular problems. Pharmaceutical therapies in this section are intended to target the underlying vascular causes and prevent additional cognitive loss. Treatment plans frequently include risk factor management, such as hypertension and diabetes.

Note: The above Chart is for representative purposes and does not depict actual sales & statistics. You can request a free sample or purchase the full report access today!

In 2023, cholinesterase inhibitors dominated the market, accounting for XX% of the total. High prescription rates for donepezil, rivastigmine, and galantamine, as well as improved results, are significant drivers of market expansion. Furthermore, the increasing use of transdermal cholinesterase inhibitors, as well as their superior safety and efficacy, are driving market expansion. For instance, Corium, LLC reported data in September 2023 indicating that Adlarity (donepezil transdermal system) demonstrated positive outcomes in terms of skin tolerability and adherence in a placebo-controlled experiment.
(Source-https://www.dermatologytimes.com/view/donepezil-patch-shows-favorable-results-on-skin-irritation-trial)
However, the combination pharmaceuticals market is expected to have the fastest compound annual growth rate (CAGR) between 2024 and 2033. This expansion is being driven by the increasing use of combination medication, which has proven to be more effective than monotherapy. Furthermore, significant players are releasing novel combination medications to the marketplace. For instance, in April 2022, NovaMedica developed and registered a combination of donepezil and memantine molecules under the brand name Mioreol in Russia and Europe. The increasing global approval of combination treatments containing cholinesterase inhibitors and NMDA receptor antagonists is propelling expansion in this segment.
(Source-https://novamedica.com/media/our_news/p/12767-novamedica-launches-own-innovative-drug-for-the-treatment-of-alzheimers-disease)

Note: The above Chart is for representative purposes and does not depict actual sales & statistics. You can request a free sample or purchase the full report access today!

Asia-Pacific Dementia Treatment Route of Administration Segment Analysis

The oral method of administration led the market in 2023 with a share of XX% and is expected to maintain its dominance in the coming years. The high market penetration of oral pharmaceuticals such as memantine, donepezil, rivastigmine, galantamine, and others, the large number of pharmaceutical companies supplying these oral drugs, and the increasing approval of oral drugs are the primary reasons driving the segment's expansion. For instance, in May 2023, the US FDA granted additional approval for Rexulti (brexpiprazole) oral tablets to treat dementia-related agitation.
(Source-https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-agitation-symptoms-associated-dementia-due-alzheimers-disease#:~:text=Today%2C%20the%20U.S.%20Food%20and,treatment%20option%20for%20this%20indication.)

The injectable pharmaceuticals segment is expected to expand at the fastest compound annual growth rate (CAGR) from 2024 to 2033. This expansion is being driven by increased research and development initiatives targeted at producing innovative biological therapies, as well as the approval of injectable medications that have demonstrated enhanced efficacy in treating dementia. For Instance, in July 2021, Biogen and Eisai Co., Ltd. got FDA approval for Aduhelm injectable to treat dementia caused by Alzheimer's disease.
(Source-https://www.eisai.com/news/2021/news202141.html)

• Oral
• Transdermal Patch
• Injectable

Asia-Pacific Dementia Treatment Distribution Channel Segment Analysis

In 2023, hospital pharmacies dominated the market, accounting for XX% of the total. The older population's increasing hospitalization rate due to dementia is driving the segment's rise. According to the Alzheimer's Association Report 2023, there were 518 hospitalizations per 1,000 Medicare beneficiaries aged 65 and older with Alzheimer's or other types of dementia, compared to just 234 hospitalizations per 1,000 Medicare beneficiaries who did not have these disorders.
(Source-https://www.alzsd.org/wp-content/uploads/2023/03/Michelle-Reuwers-Summary-of-the-2022-Alzheimers-Disease-Facts-and-Figures-Report.pdf)

On the other side, the internet category is expected to develop at the fastest compound annual growth rate (CAGR) between 2024 and 2033. This expansion is being driven by factors such as an expanding internet and smartphone user base, the convenience of obtaining drugs through e-commerce platforms, and the increased availability of online pharmacies around the globe. Furthermore, the increased use of telemedicine to manage mental health is projected to fuel growth in this segment in the coming years.

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Asia-Pacific Dementia Treatment Country Analysis

In this section we have included market revenue, share, type, application and other segment analysis for each country level. Our team identifies and analyses potential risks associated with operating in each country, including rules and regulations, geopolitical risks, and other market-specific challenges. We estimate historical data and forecast future trends to understand the market's current situation in each country. This analysis helps key players to build strategies to strengthen their foothold in Asia-Pacific Dementia Treatment market.

• China
• Japan
• South Korea
• India
• Australia
• Singapore
• Taiwan
• South East Asia
• Rest of APAC

The Current Published report Editon on the website includes the following list of countries analysis whereas in case you looking to access any other country or states level data under Asia Pacific then please revert us to access the exclusive Asia-Pacific Dementia Treatment industry report Edition.

The above graph is for illustrative purposes only. To learn more about geographical trends request the free sample pages. Contact US!

The base years considered for all the estimations by analyzing trends and growth rate will help you gain an in-depth understanding of the conclusions provided in this report. This report also includes figures, graphs, pie charts, tables and bar graphs that explain the data analysis based on current trends at the country level as well as key regions. This research report also focuses on assessing factors such as profit, product price, capacity, production, supply demand market growth rate along with others to create a clear picture on the future prospects of this market.

Author's Conclusion

Author's Detail

Supriya Yadav

Research Analyst at Cognitive Market Research

LinkedIn | Profile | Book Appointment

Supriya Yadav is a skilled market researcher with strong expertise in the Medical Devices and Consumables industry. Known for her analytical precision and deep interest in healthcare innovation, she focuses on decoding key market trends, technological advancements, and evolving customer needs. Supriya excels at transforming complex industry data into meaningful insights that support strategic decision-making for healthcare stakeholders. Her commitment to understanding the future of medical technologies and improving patient-centric solutions makes her a valuable contributor in this rapidly advancing sector.